Drug Search Results
More Filters [+]

Moroctocog alfa

Alternative Names: moroctocog alfa, Moroctocog-alfa (AF-CC)
Latest Update: 2020-11-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FVIII Mimetic

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Lebanon | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Moroctocog alfa

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2015-003685-88

P1

Active, not recruiting

Hemophilia A

2019-07-21

Recent News Events

Date

Type

Title